NCT01505894 is a Phase 1 clinical trial of BI 409306 in Healthy, sponsored by Boehringer Ingelheim.

Who is sponsoring NCT01505894?

NCT01505894 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT01505894?

Interventions in NCT01505894: BI 409306, Placebo.

Is NCT01505894 still recruiting?

NCT01505894 is currently completed. Last updated 8 March 2024.

Are results published for NCT01505894?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-03-08 · How we verify

NCT01505894

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses

Completed Phase 1 Results posted Last updated 8 March 2024

What this trial tests

Phase 1 trial testing BI 409306 in Healthy in 83 participants. Completed in 1 July 2012.

Timeline

1 January 2012

Primary endpoint
1 July 2012

1 July 2012

Quick facts

Lead sponsor	Boehringer Ingelheim
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	83
Start date	1 January 2012
Primary completion	1 July 2012
Estimated completion	1 July 2012
Sites	1 location across Germany

Drugs / interventions tested

BI 409306 — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

Adults 21 to 80, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Maximum Concentration of BI 409306 in Plasma (Cmax) Secondary · On day 1, at -2:00 hours (pre dose) and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00 and 24:00 hours after the first dose.

Maximum measured concentration of the BI 409306 in plasma after first dose.

Group	Value	95% CI
BI 409306 25 Milligram- Young Subjects (QD)	245	± 130
BI 409306 25 Milligram- Elderly Subjects (QD)	376	± 48.0
BI 409306 50 Milligram- Young Subjects (QD)	565	± 84.6
BI 409306 50 Milligram- Young Subjects (BID)	696	± 47.8
BI 409306 50 Milligram- Elderly Subjects (QD)	1100	± 58.5
BI 409306 100 Milligram- Young Subjects (QD)	1030	± 79.2
BI 409306 100 Milligram- Elderly Subjects (QD)	1840	± 68.1

Time From Dosing to Maximum Measured Concentration of BI 409306 in Plasma (Tmax) Secondary · On day 1, at -2:00 hours (pre-dose) and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00 and 24:00 hours after the first dose.

Time from dosing to maximum measured concentration of BI 409306 in plasma (Tmax) after the first dose.

Group	Value	95% CI
BI 409306 25 Milligram- Young Subjects (QD)	0.750	0.500 – 1.52
BI 409306 25 Milligram- Elderly Subjects (QD)	0.500	0.167 – 0.750
BI 409306 50 Milligram- Young Subjects (QD)	0.500	0.333 – 0.750
BI 409306 50 Milligram- Young Subjects (BID)	0.750	0.333 – 0.750
BI 409306 50 Milligram- Elderly Subjects (QD)	0.333	0.167 – 1.00
BI 409306 100 Milligram- Young Subjects (QD)	0.500	0.333 – 0.750
BI 409306 100 Milligram- Elderly Subjects (QD)	0.500	0.333 – 1.50

Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) Secondary · On day 1, at -2:00 hours (pre-dose) and at 0:10, 0:20, 0:30, 0:45, 1:00, 1:30, 2:00, 2:30, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 14:00 and 24:00 hours after the first dose.

Area under the concentration-time curve of BI 409306 in plasma over the time interval from 0 extrapolated to infinity after first dose.

Group	Value	95% CI
BI 409306 25 Milligram- Young Subjects (QD)	548	± 142
BI 409306 25 Milligram- Elderly Subjects (QD)	594	± 48.6
BI 409306 50 Milligram- Young Subjects (QD)	955	± 97.6
BI 409306 50 Milligram- Young Subjects (BID)	1140	± 54.0
BI 409306 50 Milligram- Elderly Subjects (QD)	1510	± 70.5
BI 409306 100 Milligram- Young Subjects (QD)	1620	± 60.1
BI 409306 100 Milligram- Elderly Subjects (QD)	2840	± 56.1

Maximum Concentration of BI 409306 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss) Secondary · At 312:00 hours (pre dose) and at 312:10 , 312:20, 312:30, 312:45, 313:00, 313:30, 314:00, 314:30, 315:00, 316:00, 318:00, 320:00, 322:00, 324:00, 326:00, 336:00, 360:00, 384:00 hours post dose, for once daily and twice daily treatment.

Maximum measured concentration of the BI 409306 in plasma at steady state over a uniform dosing interval τ after last dose.

Group	Value	95% CI
BI 409306 25 Milligram- Young Subjects (QD)	348	± 71.4
BI 409306 25 Milligram- Elderly Subjects (QD)	444	± 44.2
BI 409306 50 Milligram- Young Subjects (QD)	663	± 98.0
BI 409306 50 Milligram- Young Subjects (BID)	596	± 42.8
BI 409306 50 Milligram- Elderly Subjects (QD)	1250	± 76.6
BI 409306 100 Milligram- Young Subjects (QD)	1260	± 55.4
BI 409306 100 Milligram- Elderly Subjects (QD)	2150	± 87.0

Time to Achieve Maximum Concentration of BI 409306 in Plasma at Steady State (Tmax,ss) Secondary · At 312:00 hours (pre dose) and at 312:10 , 312:20, 312:30, 312:45, 313:00, 313:30, 314:00, 314:30, 315:00, 316:00, 318:00, 320:00, 322:00, 324:00, 326:00, 336:00, 360:00, 384:00 hours post dose, for once daily and twice daily treatment.

Time from last dosing until the maximum concentration of the analyte in plasma is reached at steady state after last dose on day 14.

Group	Value	95% CI
BI 409306 25 Milligram- Young Subjects (QD)	0.750	0.333 – 0.783
BI 409306 25 Milligram- Elderly Subjects (QD)	0.500	0.333 – 0.750
BI 409306 50 Milligram- Young Subjects (QD)	0.625	0.333 – 1.02
BI 409306 50 Milligram- Young Subjects (BID)	0.750	0.500 – 1.00
BI 409306 50 Milligram- Elderly Subjects (QD)	0.417	0.167 – 1.50
BI 409306 100 Milligram- Young Subjects (QD)	0.500	0.333 – 0.750
BI 409306 100 Milligram- Elderly Subjects (QD)	0.333	0.167 – 1.50

Area Under the Concentration-time Curve of BI 409306 in Plasma at Steady State (AUCτ,ss) Secondary · At 312:00 hours (pre dose) and at 312:10 , 312:20, 312:30, 312:45, 313:00, 313:30, 314:00, 314:30, 315:00, 316:00, 318:00, 320:00, 322:00, 324:00, 326:00, 336:00, 360:00, 384:00 hours post dose, for once daily and twice daily treatment.

This endpoint calculates area under the concentration-time curve of BI 409306 in plasma at steady state over a uniform dosing interval τ after last dose on day 14.

Group	Value	95% CI
BI 409306 25 Milligram- Young Subjects (QD)	747	± 93.1
BI 409306 25 Milligram- Elderly Subjects (QD)	621	± 55.8
BI 409306 50 Milligram- Young Subjects (QD)	1070	± 125
BI 409306 50 Milligram- Young Subjects (BID)	1100	± 52.4
BI 409306 50 Milligram- Elderly Subjects (QD)	1710	± 83.6
BI 409306 100 Milligram- Young Subjects (QD)	1960	± 64.3
BI 409306 100 Milligram- Elderly Subjects (QD)	3990	± 119

Number of Young and Elderly Subjects With On-treatment Adverse Events by Treatment Group Primary · From first drug administration until the end-of-trial examination, up to 28 days.

An adverse event is defined as any untoward medical occurrence, including an exacerbation of a pre-existing condition, in a subject in a clinical investigation who received a pharmaceutical product.

Group	Value	95% CI
Placebo- Young Subjects	6
Placebo-Elderly Subjects Once Daily (QD)	3
BI 409306 25 Milligram- Young Subjects (QD)	5
BI 409306 25 Milligram- Elderly Subjects (QD)	6
BI 409306 50 Milligram- Young Subjects (QD)	4
BI 409306 50 Milligram- Young Subjects (BID)	8
BI 409306 50 Milligram- Elderly Subjects (QD)	5
BI 409306 100 Milligram- Young Subjects (QD)	8
BI 409306 100 Milligram- Elderly Subjects (QD)	8

Number of Participants With Clinically Relevant Abnormal Findings in Vital Signs, 12-lead ECG, Clinical Laboratory Tests, Physical Examination, Ophthalmological Examination and Suicidality Assessment Primary · From first drug administration until the end-of-trial examination, up to 28 days.

Number of participants with clinically relevant abnormal findings, as judged by investigator and reported as adverse event (AE), in vital signs (blood pressure, pulse rate, orthostatic test), 12-lead electrocardiogram (ECG), clinical laboratory tests (haematology, clinical chemistry, urinalysis) , physical examination, ophthalmological examination and suicidality assessment.

Vital signs

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

12-lead ECG

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

Clinical laboratory test

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

Physical examiniation

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

Ophthalmological examination

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

Suicidality assessment

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

Number of Participants Per Category of Global Tolerability Assessed by the Investigator Primary · From first drug administration until the end-of-trial examination, up to 28 days.

The investigator assessed tolerability based on adverse events and the laboratory evaluation and classified the overall tolerability according to the categories 'good', 'satisfactory', 'not satisfactory', and 'bad'. Investigator judgement based on clinical findings: "good" - No or mild adverse events (AEs) and no clinically significant (NCS) findings in any clinical assessments; "satisfactory" - mild or moderate AEs, NCS clinical findings; "not satisfactory" - moderate/severe AEs and/or clinically significant (CS) findings.

Group	Value	95% CI
Placebo- Young Subjects	11
Placebo-Elderly Subjects Once Daily (QD)	9
BI 409306 25 Milligram- Young Subjects (QD)	9
BI 409306 25 Milligram- Elderly Subjects (QD)	9
BI 409306 50 Milligram- Young Subjects (QD)	9
BI 409306 50 Milligram- Young Subjects (BID)	9
BI 409306 50 Milligram- Elderly Subjects (QD)	8
BI 409306 100 Milligram- Young Subjects (QD)	9
BI 409306 100 Milligram- Elderly Subjects (QD)	8
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	1
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

Number of Participants With Abnormal Findings in Color Discrimination Test Primary · From first drug administration until the end-of-trial examination, up to 28 days.

Color vision was tested using the Ishihara test for color deficiency. The test consisted of a number of plates, called Ishihara plates, each of which contains a circle of dots of differing color and size. Within the pattern some dots form a number visible to those with normal color vision and invisible, or difficult to see, for those with a color vision deficiency. Participants with abnormal findings in color discrimination test are participants, who are not able to recognize the sign on the presented table.

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	1
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	0

Number of Participants With Abnormal Findings in Visual Acuity Test Primary · From first drug administration until the end-of-trial examination, up to 28 days.

Snellen chart was used to measure visual acuity. It measures the smallest line that a participant was able to read at a distance of 3 meter. Participants with abnormal findings in visual acuity test are participants, who are not able to recognize the letters on the line 3.

Group	Value	95% CI
Placebo- Young Subjects	0
Placebo-Elderly Subjects Once Daily (QD)	0
BI 409306 25 Milligram- Young Subjects (QD)	0
BI 409306 25 Milligram- Elderly Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (QD)	0
BI 409306 50 Milligram- Young Subjects (BID)	0
BI 409306 50 Milligram- Elderly Subjects (QD)	0
BI 409306 100 Milligram- Young Subjects (QD)	0
BI 409306 100 Milligram- Elderly Subjects (QD)	1

Adverse events — posted to ClinicalTrials.gov

Time frame: From first drug administration until the end-of-trial examination, up to 28 days.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo- Young Subjects

Serious: 0/12 (0%)

Deaths: 0/12

Placebo-Elderly Subjects Once Daily (QD)

Serious: 0/9 (0%)

Deaths: 0/9

BI 409306 25 Milligram- Young Subjects (QD)

Serious: 0/9 (0%)

Deaths: 0/9

BI 409306 25 Milligram- Elderly Subjects (QD)

Serious: 0/9 (0%)

Deaths: 0/9

BI 409306 50 Milligram- Young Subjects (QD)

Serious: 0/9 (0%)

Deaths: 0/9

BI 409306 50 Milligram- Young Subjects (BID)

Serious: 0/9 (0%)

Deaths: 0/9

BI 409306 50 Milligram- Elderly Subjects (QD)

Serious: 0/8 (0%)

Deaths: 0/8

BI 409306 100 Milligram- Young Subjects (QD)

Serious: 0/9 (0%)

Deaths: 0/9

BI 409306 100 Milligram- Elderly Subjects (QD)

Serious: 0/9 (0%)

Deaths: 0/9

Other adverse events (38 terms — click to expand)

Reaction	System	Placebo- Young Subjects	Placebo-Elderly Subjects O…	BI 409306 25 Milligram- Yo…	BI 409306 25 Milligram- El…	BI 409306 50 Milligram- Yo…	BI 409306 50 Milligram- Yo…	BI 409306 50 Milligram- El…	BI 409306 100 Milligram- Y…	BI 409306 100 Milligram- E…
Photophobia	Eye disorders	—	—	—	—	—	—	—	—	—
Photopsia	Eye disorders	—	—	—	—	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—
Chromatopsia	Eye disorders	—	—	—	—	—	—	—	—	—
Visual impairment	Eye disorders	—	—	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Flatulence	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—
Paraesthesia	Nervous system disorders	—	—	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—
Cerumen impaction	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—
Abnormal sensation in eye	Eye disorders	—	—	—	—	—	—	—	—	—
Asthenopia	Eye disorders	—	—	—	—	—	—	—	—	—
Eye pain	Eye disorders	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Faeces hard	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—
Rhinitis	Infections and infestations	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Dysgeusia	Nervous system disorders	—	—	—	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—	—	—	—
Nervousness	Psychiatric disorders	—	—	—	—	—	—	—	—	—
Withdrawal syndrome	Psychiatric disorders	—	—	—	—	—	—	—	—	—
Dysmenorrhoea	Reproductive system and breast disorders	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Nasal dryness	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT01505894 adverse events section.

Sponsor's own description

The primary objective of this trial was to investigate safety and tolerability of multiple doses of BI 409306 in healthy young and elderly volunteers. The secondary objective was to explore the pharmacokinetics and pharmacodynamics of multiple doses of BI 409306 in healthy young and elderly volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of BI 409306

Trials testing the same drug.

NCT04602221 — A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ket · Phase 1 · completed
NCT03934203 — This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study) · Phase 1 · completed
NCT03505151 — This Study in Healthy Men and Women Tests How the Body Takes up BI 409306 · Phase 1 · completed
NCT03351244 — This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Wel · Phase 2 · terminated
NCT03230097 — This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndro · Phase 2 · terminated

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Boehringer Ingelheim trials

Trials by the same sponsor.

NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01505894 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
Last refreshed: 8 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01505894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01505894

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of BI 409306

Other recruiting trials for Healthy

Other Boehringer Ingelheim trials

Verify against primary sources